BCAL Diagnostics Limited (ASX:BDX)
Australia flag Australia · Delayed Price · Currency is AUD
0.1150
0.00 (0.00%)
Feb 4, 2026, 3:46 PM AEST

BCAL Diagnostics Income Statement

Millions AUD. Fiscal year is Jul - Jun.
Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '25 Jun '24 Jun '23 Jun '22 Jun '21
Operating Revenue
0.02--0.720.28
Other Revenue
2.633.052.79--
2.653.052.790.720.28
Revenue Growth (YoY)
-13.01%9.18%288.29%161.09%-37.74%
Gross Profit
2.653.052.790.720.28
Selling, General & Admin
3.533.612.761.460.37
Research & Development
4.464.364.471.910.66
Operating Expenses
9.699.137.583.771.21
Operating Income
-7.04-6.08-4.79-3.05-0.93
Interest Expense
-0.09-0.1-0.02--
Interest & Investment Income
0.180.050.06--
Other Non Operating Income (Expenses)
-0.3-0.27-0.32-0.34-0.59
Pretax Income
-7.24-6.4-5.06-3.39-1.52
Net Income
-7.24-6.4-5.06-3.39-1.52
Net Income to Common
-7.24-6.4-5.06-3.39-1.52
Shares Outstanding (Basic)
360246211204135
Shares Outstanding (Diluted)
360246211204135
Shares Change (YoY)
46.04%16.75%3.24%51.65%17.28%
EPS (Basic)
-0.02-0.03-0.02-0.02-0.01
EPS (Diluted)
-0.02-0.03-0.02-0.02-0.01
Free Cash Flow
-6.92-5.67-6.41-3.25-1.21
Free Cash Flow Per Share
-0.02-0.02-0.03-0.02-0.01
Gross Margin
100.00%100.00%100.00%100.00%100.00%
Operating Margin
-265.55%-199.51%-171.55%-424.13%-339.30%
Profit Margin
-273.21%-210.07%-181.39%-471.08%-554.03%
Free Cash Flow Margin
-261.23%-186.23%-229.72%-451.54%-439.70%
EBITDA
-6.31-5.73-4.73-3.03-0.93
EBITDA Margin
-238.01%-188.16%-169.45%--
D&A For EBITDA
0.730.350.060.020.01
EBIT
-7.04-6.08-4.79-3.05-0.93
EBIT Margin
-265.55%-199.51%-171.55%--
Updated Jun 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.